中国临床药理学与治疗学2024,Vol.29Issue(12) :1337-1343.DOI:10.12092/j.issn.1009-2501.2024.12.003

CDA C435T基因多态性显著延长吉西他滨治疗晚期非小细胞肺癌远期疗效

CDA C435T gene polymorphism significantly extends the long-term efficacy of gemcitabine in advanced non-small cell lung cancer

王梦娇 高超 王涛 张倩 文娟 吕冬梅 胡丽丽
中国临床药理学与治疗学2024,Vol.29Issue(12) :1337-1343.DOI:10.12092/j.issn.1009-2501.2024.12.003

CDA C435T基因多态性显著延长吉西他滨治疗晚期非小细胞肺癌远期疗效

CDA C435T gene polymorphism significantly extends the long-term efficacy of gemcitabine in advanced non-small cell lung cancer

王梦娇 1高超 2王涛 3张倩 3文娟 4吕冬梅 3胡丽丽1
扫码查看

作者信息

  • 1. 徐州医科大学药学院,徐州 221000,江苏;徐州医科大学附属医院药学部,徐州 221000,江苏
  • 2. 徐州医科大学附属医院肿瘤内科,徐州 221000,江苏
  • 3. 徐州医科大学附属医院药学部,徐州 221000,江苏
  • 4. 徐州医科大学附属医院病案室,徐州 221000,江苏
  • 折叠

摘要

目的:探讨胞苷脱氨酶(cytidine deami-nase,CDA)C435T 基因多态性对吉西他滨治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)远期疗效的影响.方法:收集2016年8月至2019年2月徐州医科大学附属医院接受吉西他滨-铂类治疗的非小细胞肺癌病例145例,记录年龄、性别、病理类型、临床分期(Ⅰ-Ⅲ A/Ⅲ B-Ⅳ)等基本临床特征,依据RECIST1.1标准评估,无病生存期(DFS)、无进展生存期(PFS)及总生存期(OS)为主要终点.检测CDA C435T基因型,病例分为野生型CC组与突变型CT/TT组.采用Kaplan-Meier法和 log-rank 检验分析 CDA C435T 与 DFS、PFS 及 OS的关系,Cox模型分析预后影响因素.结果:Ⅰ-ⅢA期CC较CT/TT中位DFS延迟趋势不明显(16.8个月vs.35.7个月,P=0.294),中位OS无差异(54.3个月vs.81.9 个月,P=0.256).Ⅲ B-Ⅳ期 CT/TT 比 CC 中位PFS延长(10.4个月vs.5.0个月,P=0.009),中位OS 无差异(16.2 个月 vs.24.3 个月,P=0.087).CC和CT/TT总体中位OS无差异(21.5个月vs.25.3个月,P=0.077).Cox 回归模型显示,CDA C435T是ⅢB-Ⅳ期PFS的独立影响因素(P=0.019).结论:CDA C435T基因多态性对吉西他滨治疗Ⅲ B-Ⅳ期NSCLC的PFS具有预测性,CT/TT型明显延长.

Abstract

AIM:To research the effects of cyti-dine deaminase(CDA)C435T polymorphism on the long-term effectiveness of gemcitabine in non-small cell lung cancer(NSCLC).METHODS:Enrolled 145 NSCLC patients received gemcitabine-platinum regiments at the Affiliated Hospital of Xuzhou Med-ical University from August 2016 to February 2019,characteristics recorded such as:age,gender,path-ological type,clinical stage(Ⅰ-ⅢA/ⅢB-Ⅳ)and so on.Followed-up and evaluated according to RECIST1.1,the disease-free survival(DFS),progression-free survival(PFS)and overall survival(OS)was study endpoint.Cases were categorized into wild-type CC and mutant CT/TT group.Kaplan-Meier method and log-rank test were utilized to analyze the rela-tionship between CDA C435T and DFS/PFS/OS.A cox model was implemented to analyze the prog-nostic factors.RESULTS:In stage Ⅰ-ⅢA,median DFS of CT/TT compared with CC was not obvious(16.8 vs.35.7 months,P=0.294),same in median OS(54.3 vs.81.9 months,P=0.256).In stage ⅢB-Ⅳ,the median PFS in CT/TT was longer than CC(10.4 vs.5.0 months,P=0.009),the median OS was undiffer-entiated(16.2 vs.24.3 months,P=0.087).No differ-ence of overall median OS in CC and CT/TT geno-types was seen(21.5 months vs.25.3 months,P=0.077).Cox regression model showed CDA C435T polymorphism was an independent factor of PFS in stage ⅢB-Ⅳ(P=0.019).CONCLUSION:CDA C435T polymorphism shows a function as a prediction in-fluencing PFS of gemcitabine in ⅢB-Ⅳ NSCLC,CT/TT genotype is significantly prolonged.

关键词

CDA/C435T基因/非小细胞肺癌/化疗/多态性/预后

Key words

CDA C435T gene/non-small cell lung cancer/chemotherapy/polymorphism/prognosis

引用本文复制引用

出版年

2024
中国临床药理学与治疗学
中国药理学会

中国临床药理学与治疗学

CSTPCD北大核心
影响因子:0.97
ISSN:1009-2501
段落导航相关论文